SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is trending as escalating Middle East tensions, including the Strait of Hormuz disruption and production cuts, initially sent oil prices soaring. However, immediate market conversation has shifted to the G7 and IEA's reported announcement of a massive strategic oil reserve release, prompting debate on whether the rally will continue or if a sharp downturn is imminent.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending after resolving its legal dispute with Novo Nordisk and partnering to offer FDA-approved GLP-1 weight-loss medications on its platform, eliminating a significant bear thesis. This development has ignited strong bullish sentiment, with the community actively discussing a potential short squeeze due to high short interest and anticipating analyst upgrades.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disney is trending following a Q1 earnings beat with record theme park revenue and improved streaming profitability, alongside the announcement of Josh D'Amaro as the new CEO; however, community sentiment remains divided, balancing strong fundamentals and a share buyback against lingering concerns over content strategy, linear TV pressures, and the company's aggressive stance on AI IP infringement.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

The community is actively discussing FuelCell Energy's potential in the surging AI data center market, following its Q1 revenue growth and a strategic collaboration targeting 450 MW for power solutions; however, many remain skeptical of management's ability to convert pipeline opportunities into definitive contracts amidst ongoing share dilution.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as excitement surges following a cryptic tweet from "Roaring Kitty," reigniting fervent retail investor discussions about a potential short squeeze. The community also eyes upcoming earnings and anticipates strategic announcements from Ryan Cohen for the heavily shorted stock.

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.

AN2 Therapeutics Inc

AN2 Therapeutics is gaining attention following updates indicating clinical improvements for its epetraborole program and plans to discuss re-initiating a Phase 3 study, reversing a prior setback that caused a significant drop. This, combined with new strategic collaborations, financing, and recent insider buying, has sparked a community discussion between optimistic bulls targeting substantial gains and cautious observers anticipating further volatility.

ProShares Trust - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

SCO is trending as traders anticipate a sharp reversal in crude oil prices, which have seen extreme volatility amid escalating Middle East geopolitical tensions and concerns over the Strait of Hormuz. The community is actively buying into this inverse ETF, betting that oil's fear-driven rally is overblown and that prices will inevitably fall, though some debate the ETF's tracking and risk of a reverse split.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending due to heightened global geopolitical tensions and rising oil prices, prompting community discussion around an imminent market volatility spike and a potential correction. Many are positioning for upside in the VIX (fear gauge) as a hedge, while others caution against the leveraged ETF's inherent decay.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Relmada Therapeutics Inc

Relmada Therapeutics is trending on the back of positive 12-month Phase 2 interim data for its NDV-01 bladder cancer treatment and a substantial private placement. Community discussion highlights the drug's high response rates and insider buying, alongside concerns regarding dilution and the company's funding path.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd. is trending amid sharply rising crude oil prices driven by escalating Middle East tensions, leading to intense debate among investors over its potential for a major short squeeze versus ongoing concerns about market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CORT revenue climbing… but a legal cloud is forming. ⚖️📈

Korlym sales jumped 13% Y/Y in 2025, fueling Corcept’s growth, and 2026 revenues are seen at $900M–$1B — a strong trajectory if momentum holds.

But a court ruling favoring Teva’s generic could put pressure on future Korlym sales, creating a key risk investors can’t ignore.

Full risk/reward picture here 👉 https://www.zacks.com/stock/news/2879144/corcepts-korlym-drives-its-2025-revenue-surge-whats-ahead?cid=sm-stocktwits-2-2879144-teaser-36119&amp;ADID=SYND_STOCKTWITS_TWEET_2_2879144_TEASER_36119

Zacks

Pardon Our Interruption

Zacks Research

Corcept Therapeutics Inc

 revenue climbing… but a legal cloud is forming. ⚖️📈

Korlym sales jumped 13% Y/Y in 2025, fueling Corcept’s growth, and 2026 revenues are seen at $900M–$1B — a strong trajectory if momentum holds.

But a court ruling favoring Teva’s generic could put pressure on future Korlym sales, creating a key risk investors can’t ignore.

Full risk/reward picture here 👉 

This account is recognized as an Official Stocktwits Research Partner — working in close collaboration with Stocktwits to deliver in-depth research and market analysis.